The $100 Trillion Threat: Why Pharma Must Partner with Community Infrastructure to Defeat AMR and Sepsis
By Gareth Presch
CEO & Founder, World Health Innovation Summit (WHIS) & Global Social Prescribing Alliance
World Health Innovation Summit
Antimicrobial Resistance (AMR) is no longer a looming theoretical crisis. It is a slow-motion pandemic that threatens to dismantle the foundation of modern medicine.
If left unchecked, AMR is projected to cause an astronomical $100 trillion loss to global GDP by 2050. Common surgeries, routine cancer treatments, and childbirth could once again become life-threatening procedures because the antibiotics we rely on simply no longer work.
Yet, the traditional economic engine for discovering new antimicrobials is fundamentally broken. Developing a new antibiotic costs billions, but because of essential stewardship, these drugs must be kept on the shelf as a last resort. For the pharmaceutical sector, this mismatch has led to a collapsing commercial pipeline, market exits, and deep financial risk.
We cannot expect pharmaceutical companies to fix this broken market entirely on their own. If we want to change the economics of AMR and Sepsis, we must re-engineer how we preserve and deliver medicine at the community level.
Today, the World Health Innovation Summit (WHIS) and our global partners are launching a unified public call to action: The 1% for Health Campaign. We are inviting forward-thinking pharmaceutical leaders, life sciences corporations, and institutional healthcare investors to pledge 1% of annual corporate profits (or dedicated Impact and Sustainability budgets) to scale a permanent, global line of defense via our Global AMR & Sepsis Innovation Hubs.
Protecting the Pipeline: Why Community Infrastructure Matters to Pharma
For major life science companies, investing in our global hubs isn’t a passive act of charity; it is a strategic investment in protecting the longevity and efficacy of your entire drug portfolio.
Through our partnership with Dr. Ron Daniels (global AMR specialist, sepsis expert, and vice-president of our emerging disease initiatives), our innovation hubs shift the battlefield from reactive hospital triage to proactive community management.
[ PHARMA 1% IMPACT CAPITAL ]
│
▼
┌─────────────────────────────────────────┐
│ GLOBAL AMR & SEPSIS INNOVATION HUBS │
└────────────────────┬────────────────────┘
│
┌─────────────────────────┼─────────────────────────┐
▼ ▼ ▼
[ STEWARDSHIP & ECO ] [ FRONT CAPACITY ] [ COMPREHENSIVE CARE ]
Lifestyle Medicine & Task-Sharing and Social Prescribing
Precision Diagnostics Rapid Sepsis Diagnostics Alleviating System Strain
│ │ │
└─────────────────────────┼─────────────────────────┘
▼
[ THE PHARMA BENEFIT MATRIX ]
• Extended clinical efficacy of existing portfolios
• Audited, place-based Social Return on Investment (SROI)
• Direct alignment with Global Health Equity & Sustainability
By channeling 1% impact capital through our financial vehicle, the World Health Service (WHS), and our US 501(c)(3) public charity partner (Legacy Global Programs, EIN: 20-8099462), life sciences partners directly fund a comprehensive operational model:
World Health Innovation Summit
- Precision Stewardship and Diagnostics: Equipping our regional deployment teams with lifestyle medicine frameworks and rapid point-of-care diagnostics. This prevents the inappropriate over-prescribing of antibiotics for viral infections, directly extending the clinical usefulness and commercial lifespan of existing drug portfolios.
- Frontline Task-Sharing for Sepsis: Training non-clinical community health workers to spot the early warning signs of infection deterioration. Early community intervention saves lives, stops sepsis before it requires critical ICU resources, and prevents the massive, broad-spectrum antibiotic overuse that fuels hospital-acquired resistance.
- The Holistic Wrap Around Vulnerable Groups: Integrating advanced clinical monitoring with the global framework of social prescribing. By connecting high-risk groups—such as cancer patients, individuals living with Motor Neuron Disease (MND), and the isolated elderly—to structured social support (Green, Blue, and Practical care), we keep them clear of microbially dense, resistant hospital environments entirely.
Globally Scaled, Locally Delivered: Chapter-Backed Impact
The biggest barrier to institutional scale is ensuring your investment translates directly into frontline results. We solve this through our active Global Chapter Network spanning the UK, the USA, Italy, Portugal, Ireland, the Netherlands, Spain, the Nordic countries, India, and Argentina.
Our local chapters allow pharmaceutical partners to co-design and anchor localized solutions where they have a significant commercial or manufacturing footprint. Furthermore, for institutions looking to create a multi-generational legacy, we utilize our chapter network to establish localized endowment funds.
By investing your 1% profit contribution into a permanent, income-generating capital base, we ensure that local infection management programs, community diagnostic tools, and clinical stewardship frameworks are funded in your targeted territories in perpetuity.
An Invitation to Co-Design the Future of Health Equity
We are currently convening a select cohort of 15 Global Founding Partners across the life sciences, banking, and philanthropic sectors to anchor the launch of this framework.
👉** View the complete strategic hub proposal**:[ Global AMR & Sepsis Innovation Hubs
The pharmaceutical industry has achieved miracles in drug discovery, but the AMR crisis cannot be cured by chemistry alone. It requires a resilient financial and community infrastructure that protects our collective medical future.
Let’s move past short-term, siloed funding. Let’s co-create a sustainable, unconstrained future for global infection management.
Join the movement. Let’s protect modern medicine together.
Contact: whis.world | gareth@whis.world
Relevant Briefing Discussion
To see this framework discussed in action by the executive team, watch this recorded segment from the WHIS 2024 Emerging Diseases Panel on AMR . This video is highly relevant as it features Dr. Ron Daniels and the panel outlining the $100 trillion economic risk of AMR and discussing the exact cross-sector, sustainable healthcare investment strategies that inform this 1% campaign blog.